bevacizumab (Abevmy / bevacizumab, Biocon / Krabeva)

High rates of venous thromboembolism in endometrial cancer patients requiring systemic therapy: an opportunity for risk assessment and intervention.

Thayer Elizabeth G EG, Roecker Zoe A ZA, Roof Kelsey A KA, Gold Hannah B HB et al.

We aim to describe the venous thromboembolism (VTE) rate among patients who received chemotherapy for initial endometrial cancer treatment, and identify factors associated with VTE diagnosis in this population. This is a retrospective cohort study of patients who received chemotherapy during initial treatment for endometrial cancer from January 2015 to December 2023 within a single academic medical system. The primary outcome is overall VTE incidence. Sociodemographic and biomedical factors were collected. Descriptive statistics were used for analysis. Two hundred ninety-two patients were identified who received chemotherapy during initial treatment for endometrial cancer; 78 (26.7%) developed a VTE after cancer diagnosis. Cancer stage was associated with VTE development (p < 0.001); 50.0% of patients who developed VTE had Stage IV at diagnosis compared to 20.4% of those who did not. Twenty-four patients (30.8%) had carcinomatosis at the time of VTE diagnosis and 14 (17.9%) had ascites. A high-risk Khorana score (≥3) at initiation of initial chemotherapy, histology, grade, age, ECOG functional status, tobacco use, body mass index, and receipt of external beam pelvic radiation, immunotherapy, or bevacizumab during initial treatment were not associated with VTE development. More than 1 in 4 patients who received chemotherapy for initial endometrial cancer developed a VTE during their treatment course. Stage at cancer diagnosis was the only factor associated with subsequent VTE; factors including histology, grade, BMI and Khorana score were not associated. As endometrial cancer incidence rises, continued efforts to improve the accuracy of risk assessment tools and evaluate prophylactic anticoagulation in this high-risk population are warranted.

Clinical outcomes and prognostic factors in advanced high-grade platinum-resistant ovarian carcinoma: evidence from the ESME real-world cancer database.

Heurtier Victor V, Macouillard Pauline P, Ray-Coquard Isabelle I, Sabatier Renaud R et al.

We aimed to describe real-world outcomes of chemotherapy with or without bevacizumab in patients with platinum-resistant high-grade serous ovarian, peritoneal, or fallopian tube carcinoma and to identify prognostic factors. We retrospectively analyzed the French ESME Ovarian Cancer national database. Eligible patients had high-grade ovarian carcinoma after one to three prior treatment lines and received, in the first platinum-resistant setting, paclitaxel, pegylated liposomal doxorubicin, or gemcitabine, with or without bevacizumab. Because of baseline differences, chemotherapy-alone and chemotherapy-plus-bevacizumab groups were analyzed separately. Progression-free survival and overall survival were estimated using Kaplan-Meier methods and multi-variable Cox models. A total of 688 patients were included: 580 (84.3%) received chemotherapy alone and 108 (15.7%) chemotherapy plus bevacizumab. Median progression-free survival and overall survival were 3.2 and 8.8 months. In the chemotherapy-alone group, gemcitabine was associated with inferior progression-free survival compared with paclitaxel (2.5 vs 3.4 months; hazard ratio [HR] 1.31; 95% confidence interval [CI] 1.03 to 1.67), with no significant overall survival difference between regimens. In the bevacizumab group, median progression-free survival was 6.5 months with paclitaxel plus bevacizumab, compared with 4.1 months with pegylated liposomal doxorubicin plus bevacizumab (HR 3.50, 95% CI 1.93 to 6.34) and 3.6 months with gemcitabine plus bevacizumab (HR 2.54, 95% CI 1.10 to 5.88). Pegylated liposomal doxorubicin plus bevacizumab was also associated with worse overall survival than paclitaxel plus bevacizumab (median 9.8 vs 13.4 months; HR 1.99, 95% CI 1.04 to 3.81). In the overall multi-variable model, bevacizumab was independently associated with improved overall survival (HR 0.73, 95% CI 0.56 to 0.94). Eastern Cooperative Oncology Group (ECOG) performance status ≤1 and longer time to platinum resistance were consistent favorable prognostic factors. ECOG and time to platinum resistance were the strongest prognostic factors. Paclitaxel-based regimen appeared more favorable when combined with bevacizumab, although exploratory. The independent association between bevacizumab and improved overall survival should be interpreted cautiously, likely reflecting confounding by indication.

Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy versus bevacizumab combined with chemotherapy in first-line treatment of driver gene-negative advanced non-squamous non-small cell lung cancer: a single-center retrospective study.

Mo Wenqiang W, Li Yinzhen Y, Zhao Luna L, Liu Yuan Y et al.

To compare the efficacy and safety of immune checkpoint inhibitors (ICIs) versus bevacizumab (both combined with chemotherapy) for first-line treatment of driver gene-negative advanced non-squamous non-small cell lung cancer (NSCLC). This single-center retrospective study enrolled 194 patients with driver gene-negative advanced non-squamous NSCLC treated at our hospital from May 1, 2019, to May 1, 2025: 79 received ICIs plus chemotherapy, and 115 received bevacizumab plus chemotherapy. Both groups received 4-6 cycles of combination therapy followed by maintenance therapy until disease progression or the end of the study. The primary endpoint was progression-free survival (PFS), and secondary endpoints included objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). Short-term efficacy: ORR was significantly higher in the ICIs plus chemotherapy group than in the bevacizumab plus chemotherapy group (41.77% vs 26.09%, P = 0.022), while DCR showed no statistically significant difference between groups (84.81% vs 79.13%, P = 0.317). Survival benefit: Median PFS was 14.330 months in the ICIs plus chemotherapy group, which was superior to 9.60 months in the bevacizumab plus chemotherapy group (P = 0.014). Safety: The ICIs plus chemotherapy group had a higher incidence of thyroid dysfunction (8.86% vs 0%, P = 0.002), immune-related pneumonitis (3.80% vs 0%, P = 0.066) and immune-related hepatitis (5.06% vs 0%, P = 0.026); the bevacizumab plus chemotherapy group had a higher incidence of proteinuria (7.83% vs 0%, P = 0.012) and hypertension (6.96% vs 0%, P = 0.022). Other AEs were comparable between the two groups. Subgroup analysis: Higher disease progression risk was observed in the bevacizumab plus chemotherapy group for patients with PD-L1 high expression (HR = 3.731, P = 0.039), indicating this population benefits more from ICIs plus chemotherapy. Higher progression risk was seen in the ICIs plus chemotherapy group for males (HR = 2.410, P = 0.015), ever-smokers (HR = 2.215, P = 0.047), patients with ECOG score 0-1 (HR = 1.762, P = 0.032) and patients without bone metastasis (HR = 2.112, P = 0.036), suggesting these subgroups are more likely to benefit from bevacizumab plus chemotherapy. For patients with driver gene-negative advanced non-squamous NSCLC, ICIs combined with chemotherapy are superior to bevacizumab combined with chemotherapy in terms of short-term efficacy and progression-free survival, with manageable but distinct adverse event profiles.

Reconsidering Low-Dose Bevacizumab Regimens in High-Grade Gliomas: A Policy Brief for Resource-Limited Settings.

Parivar Yegane Y, Fazilat-Panah Danial D, Welsh James S JS, Peyro Shabany Babak B et al.